Zydus Lifesciences Ltd has signed an exclusive agreement with US-based Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India, expanding access to precision oncology tools nationwide.
Under the agreement, Zydus will market and promote Myriad’s MyRisk Hereditary Cancer Test, MyChoice HRD Plus homologous recombination deficiency test, and the Prolaris prostate cancer prognostic test for patients, clinicians and healthcare systems across the country.
The diagnostic portfolio is aimed at supporting personalised cancer care by providing clinically actionable genomic insights. The MyRisk test evaluates multiple clinically significant genes to assess inherited cancer risk and guide screening and prevention strategies.
The MyChoice HRD Plus test helps determine HRD status in ovarian cancer, which can influence targeted treatment decisions, while the Prolaris test measures tumour aggressiveness in prostate cancer to support prognosis and therapy planning.
Zydus will have exclusive rights in India to drive clinician engagement and awareness of these globally validated diagnostic platforms, which are designed to improve risk assessment, personalise treatment planning, predict disease progression and streamline clinical workflows.
The partnership is expected to strengthen precision diagnostics and enhance cancer management capabilities across the Indian healthcare ecosystem.
